glp-1 drug least chemical modification GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications PDB-101: Diabetes Mellitus: Diabetes Mellitus:
Description
Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials
Michael, et al
[DOI] [PubMed] [Google Scholar] 104.Zhang Y, Chen R, Jia Y, Chen M, Shuai Z
10 , e020237 (2021)
At Cape Fear Physical Medicine and Rehab, we recognize that weight management is a critical component of overall health and physical well-being
The duration of follow-up varied from 5 weeks to over 3 years, once again demonstrating both short-term and long-term benefits of GLP-1RAs in managing albuminuria and improving kidney outcomes
